Correspondence
Lovastatin for X-Linked Adrenoleukodystrophy
N Engl J Med 1998; 339:702-703September 3, 1998
- Article
To the Editor:
X-linked adrenoleukodystrophy is an inherited recessive disorder characterized by a defect in peroxisomal β-oxidation of very-long-chain fatty acids (those with more than 22 carbon atoms) and secondary neuroinflammatory damage.1,2 Even though the accumulation of very-long-chain fatty acids in plasma and tissues occurs early, the neurologic manifestations are not observed until the age of 4 to 8 years for childhood adrenoleukodystrophy or 20 to 30 years for adrenomyeloneuropathy. The neurologic damage in X-linked adrenoleukodystrophy may be mediated by the activation of astrocytes and the induction of proinflammatory cytokines. At present, dietary restrictions and therapy with Lorenzo's oil are used to lower plasma levels of very-long-chain fatty acids, but these measures do not address the neuroinflammatory aspects of the disorder.1,2
Recently, in animal studies, we have shown that lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and sodium phenylacetate, an inhibitor of mevalonate pyrophosphate decarboxylase, inhibit the induction of inducible nitric oxide synthase and proinflammatory cytokines (tumor necrosis factor α, interleukin-1β, and interleukin-6) involved in the pathogenesis of neurologic damage in X-linked adrenoleukodystrophy.3 We have also shown that lovastatin, sodium phenylacetate,4 and compounds that increase intracellular cyclic AMP and protein kinase A activity 5 normalize the levels of very-long-chain fatty acids in cultured skin fibroblasts from patients with childhood adrenoleukodystrophy and adrenomyeloneuropathy.
We have treated seven patients from three families with lovastatin for two to six months. The study was approved by the institutional review board at our medical school, and the patients provided informed consent. The diagnosis was established in each case by clinical findings and documentation of elevated plasma levels of total very-long-chain fatty acids by two different laboratories. Each patient was treated with 20 mg of lovastatin per day for two weeks; the dose was increased to 40 mg per day if no adverse effects were noted. Plasma total very-long-chain fatty acids were measured periodically throughout the study. Adverse events and compliance were assessed on the basis of the patients' reports and by periodic measurement of plasma total cholesterol, creatine kinase, aspartate aminotransferase, and alanine aminotransferase.
One patient (Patient 4) was withdrawn from the study because of persistent diarrhea and a marked elevation of serum creatine kinase levels. Another (Patient 5) discontinued treatment. Our results (Table 1Table 1
Effect of Lovastatin Therapy on Plasma Levels of Very-Long-Chain Fatty Acids in Patients with X-Linked Adrenoleukodystrophy.) show that plasma levels of total very-long-chain fatty acids declined from their pretreatment values within one month after the initiation of lovastatin therapy in each patient and remained low and within the normal range for up to six months in the five patients who continued the treatment. Their lower post-treatment cholesterol values (Table 1) provide evidence of compliance with therapy. The short duration and small size of the study did not allow us to assess whether there was a clinical benefit.These results suggest that lovastatin treatment may represent a simple, safe, and effective way to reduce the accumulated plasma very-long-chain fatty acids in adult patients with X-linked adrenoleukodystrophy. On the basis of this finding, together with the results of our in vitro and animal studies showing that lovastatin blocks the induction of inflammatory mediators of neurologic damage in X-linked adrenoleukodystrophy,4 we believe further evaluation of this therapeutic approach is warranted.
5 ReferencesInderjit Singh, Ph.D.
Mushfiquddin Khan, Ph.D.
Lyndon Key, M.D.
Shashidhar Pai, M.D.
Medical University of South Carolina, Charleston, SC 294251
Singh I . Biochemistry of peroxisomes in health and disease. Mol Cell Biochem 1997;167:1-29
CrossRef | Web of Science | Medline2
Moser HW, Smith KD, Moser AB. X-linked adrenoleukodystrophy. In: Scriver DR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:2325-49.
3
Pahan K ,Sheikh FG ,Namboodiri AM ,Singh I . Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-2679
CrossRef | Web of Science | Medline4
Singh I ,Pahan K ,Khan M . Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts from X-adrenoleukodystrophy. FEBS Lett 1998;426:342-346
CrossRef | Web of Science | Medline5
Pahan K ,Khan M ,Singh I . Therapy for X-adrenoleukodystrophy: normalization of very long chain fatty acids and inhibition of induction of cytokines by cAMP. J Lipid Res 1998;39:1091-1100
Web of Science | Medline
- Citing Articles (33)
Citing Articles
1
Stephan Kemp, Frederica L Theodoulou, Ronald JA Wanders. (2011) Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. British Journal of Pharmacology 164:7, 1753-1766
CrossRef2
Jiho Jang, Hoon-Chul Kang, Han-Soo Kim, Ji Young Kim, Yong Jun Huh, Dae-Sung Kim, Jeong-Eun Yoo, Jeong-Ah Lee, Boyoung Lim, Jiwon Lee, Tae-Min Yoon, In-Hyun Park, Dong-Youn Hwang, George Q. Daley, Dong-Wook Kim. (2011) Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Annals of Neurology 70:3, 402-409
CrossRef3
Ronald J. A. Wanders, Jasper Komen, Stephan Kemp. (2011) Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS Journal 278:2, 182-194
CrossRef4
Johannes Berger, Aurora Pujol, Patrick Aubourg, Sonja Forss-Petter. (2010) Current and Future Pharmacological Treatment Strategies in X-Linked Adrenoleukodystrophy. Brain Pathology 20:4, 845-856
CrossRef5
Stephan Kemp, Ronald Wanders. (2010) Biochemical Aspects of X-Linked Adrenoleukodystrophy. Brain Pathology 20:4, 831-837
CrossRef6
Isidro Ferrer, Patrick Aubourg, Aurora Pujol. (2010) General Aspects and Neuropathology of X-Linked Adrenoleukodystrophy. Brain Pathology 20:4, 817-830
CrossRef7
Nicola Neary, Lynnette Nieman. (2010) Adrenal insufficiency: etiology, diagnosis and treatment. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 217-223
CrossRef8
Rob Ofman, Inge M. E. Dijkstra, Carlo W. T. van Roermund, Nena Burger, Marjolein Turkenburg, Arno van Cruchten, Catherine E. van Engen, Ronald J. A. Wanders, Stephan Kemp. (2010) The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Molecular Medicine 2:3, 90-97
CrossRef9
Engelen, Marc, Ofman, Rob, Dijkgraaf, Marcel G.W., Hijzen, Michiel, van der Wardt, Lucinda A., , van Geel, Bjorn M., , de Visser, Marianne, Wanders, Ronald J.A., Poll-The, Bwee Tien, Kemp, Stephan, . (2010) Lovastatin in X-Linked Adrenoleukodystrophy. New England Journal of Medicine 362:3, 276-277
Full Text10
Alexander Semmler, Wolfgang Köhler, Hans H Jung, Michael Weller, Michael Linnebank. (2008) Therapy of X-linked adrenoleukodystrophy. Expert Review of Neurotherapeutics 8:9, 1367-1379
CrossRef11
Izumi Kuratsubo, Yasuyuki Suzuki, Nobuyuki Shimozawa, Naomi Kondo. (2008) Parents of childhood X-linked adrenoleukodystrophy: High risk for depression and neurosis. Brain and Development 30:7, 477-482
CrossRef12
Mushfiquddin Khan, Jaspreet Singh, Inderjit Singh. (2008) Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. Journal of Neurochemistry???-???
CrossRef13
M. Morita, M. Kanai, S. Mizuno, M. Iwashima, T. Hayashi, N. Shimozawa, Y. Suzuki, T. Imanaka. (2008) Baicalein 5,6,7-trimethyl ether activates peroxisomal but not mitochondrial fatty acid β-oxidation. Journal of Inherited Metabolic Disease 31:3, 442-449
CrossRef14
Ronald J. A. Wanders, Wouter F. Visser, Carlo W. T. Roermund, Stephan Kemp, Hans R. Waterham. (2007) The peroxisomal ABC transporter family. Pflügers Archiv - European Journal of Physiology 453:5, 719-734
CrossRef15
Frauke Zipp, Orhan Aktas. (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in Neurosciences 29:9, 518-527
CrossRef16
Marion Deon, Moacir Wajner, Lisana R. Sirtori, Douglas Fitarelli, Daniella M. Coelho, Angela Sitta, Alethéa G. Barschak, Gustavo C. Ferreira, Alexsandro Haeser, Roberto Giugliani, Carmen R. Vargas. (2006) The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. Journal of the Neurological Sciences 247:2, 157-164
CrossRef17
Mohamed A. Al-Omar. (2006) The X-Linked Adrenoleukodystrophy (X-ALD) and Oxidative Stress. Journal of Herbal Pharmacotherapy 6:3-4, 125-134
CrossRef18
Yasuyuki Suzuki, Yasuhiko Takemoto, Nobuyuki Shimozawa, Tsuneo Imanaka, Shunichi Kato, Hirokazu Furuya, Makiko Kaga, Koji Kato, Naohiro Hashimoto, Osamu Onodera, Shoji Tsuji. (2005) Natural history of X-linked adrenoleukodystrophy in Japan. Brain and Development 27:5, 353-357
CrossRef19
Hugo Moser, Prachi Dubey, Ali Fatemi. (2004) Progress in X-linked adrenoleukodystrophy. Current Opinion in Neurology 17:3, 263-269
CrossRef20
Marianne Depreter, Marc Espeel, Frank Roels. (2003) Human peroxisomal disorders. Microscopy Research and Technique 61:2, 203-223
CrossRef21
Y Suzuki. (2001) The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil. Brain and Development 23:1, 30-33
CrossRef22
Yasunobu Antoku, Kohsuke Tsukamoto, Yuji Miyoshi, Hisanori Nagino, Masaharu Anezaki, Kazuo Suwa, Yasushi Narabe. (2000) Correlations of elevated levels of hexacosanoate in erythrocyte membranes with risk factors for atherosclerosis. Atherosclerosis 153:1, 169-173
CrossRef23
Aurora Pujol, Nathalie Troffer-Charlier, Elisabeth Metzger, Giovanna Chimini, Jean-Louis Mandel. (2000) Characterization of the Adrenoleukodystrophy-Related (ALDR, ABCD2) Gene Promoter: Inductibility by Retinoic Acid and Forskolin. Genomics 70:1, 131-139
CrossRef24
Bijayeswar Vaidya, Simon Pearce, Pat Kendall-Taylor. (2000) Recent advances in the molecular genetics of congenital and acquired primary adrenocortical failure. Clinical Endocrinology 53:4, 403-418
CrossRef25
Aad Verrips, Mich
l A. A. P. Willemsen, Estela Rubio-Gozalbo, Jan De Jong, Jan A. M. Smeitink. (2000) Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy. Annals of Neurology 47:4, 552-553
CrossRef26
G. Shashidhar Pai, Mushfiquddin Khan, Ernest Barbosa, Lyndon L. Key, Jeffery R. Craver, Joel K. Curé, Renée Betros, Inderjit Singh. (2000) Lovastatin Therapy for X-Linked Adrenoleukodystrophy: Clinical and Biochemical Observations on 12 Patients. Molecular Genetics and Metabolism 69:4, 312-322
CrossRef27
Brenda E. Porter, Gihan Tennekoon. (2000) Myelin and disorders that affect the formation and maintenance of this sheath. Mental Retardation and Developmental Disabilities Research Reviews 6:1, 47-58
CrossRef28
Gerald V Raymond. (1999) Peroxisomal disorders. Current Opinion in Pediatrics 11:6, 572-576
CrossRef29
William Krivit, Patrick Aubourg, Elsa Shapiro, Charles Peters. (1999) Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Current Opinion in Hematology 6:6, 377
CrossRef30
Charles R. Scriver, Eileen P. Treacy. (1999) Is There Treatment for “Genetic” Disease?. Molecular Genetics and Metabolism 68:2, 93-102
CrossRef31
Johannes Berger, Sabrina Albet, Marc Bentejac, Angela Netik, Andreas Holzinger, Adelbert A. Roscher, Maurice Bugaut, Sonja Forss-Petter. (1999) The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. European Journal of Biochemistry 265:2, 719-727
CrossRef32
Alfred Poulos, Peter C. Stockham, David W. Johnson, Barbara C. Paton, Kaye Beckman, Harmeet Singh. (1999) Metabolism of trideuterated iso-lignoceric acid in rats in Vivo and in human fibroblasts in culture. Lipids 34:9, 943-949
CrossRef33
Monique Dubois-Dalcq, Valerie Feigenbaum, Patrick Aubourg. (1999) The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends in Neurosciences 22:1, 4-12
CrossRef
